What non‑stimulant pharmacologic options for attention‑deficit/hyperactivity disorder do not increase heart rate, excluding atomoxetine (Strattera) and viloxazine (Qelbree)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Non-Stimulant ADHD Options That Don't Increase Heart Rate

The alpha-2 adrenergic agonists—extended-release guanfacine and extended-release clonidine—are your primary non-stimulant options that actually decrease rather than increase heart rate, making them ideal when cardiovascular effects are a concern. 1

Understanding the Cardiovascular Profile

The key distinction here is critical: among FDA-approved non-stimulants for ADHD, atomoxetine (Strattera) increases heart rate and blood pressure similarly to stimulants, while guanfacine and clonidine have the opposite effect—they decrease both heart rate and blood pressure through their alpha-2 adrenergic receptor agonism 1, 2.

Guanfacine Extended-Release (Intuniv)

  • Mechanism: Alpha-2 adrenergic receptor agonist that enhances noradrenergic neurotransmission
  • Cardiovascular effects: Decreases heart rate and blood pressure (bradycardia and hypotension are potential side effects, not increases) 1, 2
  • Dosing: Once-daily administration, weight-based (approximately 0.1 mg/kg), available in 1,2,3, and 4 mg tablets 2
  • Onset: 2-4 weeks until therapeutic effects observed 2
  • Key advantages: "Around-the-clock" effects, uncontrolled substance, may help with comorbid sleep issues, tics, or disruptive behavior 2

Clonidine Extended-Release (Kapvay)

  • Mechanism: Alpha-2 adrenergic receptor agonist (same class as guanfacine)
  • Cardiovascular effects: Decreases heart rate and blood pressure; bradycardia and syncope reported 2
  • Dosing: Starting dose 0.1 mg at bedtime, can increase to twice-daily; maximum 0.4 mg/day. Also available as transdermal patch (0.1,0.2,0.3 mg) 2
  • Onset: 2-4 weeks for full effect 2
  • Key disadvantage: Requires twice-daily dosing (unlike guanfacine's once-daily) 2

Important Clinical Considerations

Common side effects of both alpha-2 agonists include somnolence/sedation (most frequent), fatigue, dry mouth, dizziness, irritability, headache, and abdominal pain 1, 2. Evening administration is generally preferable to mitigate daytime sedation 2.

Critical safety warning: Both medications must be tapered when discontinuing—never stop abruptly—due to risk of rebound hypertension 1. Baseline ECG is recommended before starting, particularly if cardiac risk factors are present 1.

Efficacy expectations: These medications have medium effect sizes, smaller than stimulants but proven efficacious 2. They work well as monotherapy or can be combined with stimulants to augment treatment and potentially reduce stimulant-related cardiovascular effects 2.

When to Choose Alpha-2 Agonists as First-Line

Consider guanfacine or clonidine as first-line options (rather than second-line) in patients with:

  • Comorbid sleep disorders
  • Substance use disorders (where stimulants are contraindicated)
  • Tic disorders or Tourette's syndrome
  • Disruptive behavior disorders
  • Cardiovascular concerns where HR/BP increases must be avoided 2

Between the two alpha-2 agonists, guanfacine is generally preferred due to once-daily dosing, potentially fewer adverse effects compared to clonidine, and better-documented long-term maintenance of treatment effects 2. Clonidine's transdermal patch formulation may be advantageous for patients with adherence issues or pill-swallowing difficulties 2.

Monitoring Requirements

  • Pulse and blood pressure at baseline and regularly during treatment 2
  • Watch for excessive sedation, particularly in first few weeks
  • Monitor for signs of hypotension (dizziness, syncope)
  • Assess for cardiac conduction abnormalities if risk factors present 2

References

Related Questions

What alternative medications can be used for attention-deficit/hyperactivity disorder, and should a daily dose of viloxazine 200 mg be tapered to 100 mg before discontinuation?
What non‑stimulant medications (e.g., viloxazine [Qelbree], atomoxetine [Strattera], bupropion) can be tried for a patient with ADHD who reports that Adderall was the only medication that helped?
In a 7‑year‑old female who develops abdominal pain and headache for about two weeks after atomoxetine dose adjustments and has tried all other ADHD medications except Qelbree (viloxazine), is Qelbree a suitable alternative?
What are alternative treatment options for ADHD when Vyvanse (lisdexamfetamine) is ineffective?
In a 58-year-old woman with adult ADHD and atypical chest pain who is intolerant to atomoxetine, which of methylphenidate, lisdexamfetamine, or guanfacine has the safest cardiac safety profile?
Will delayed ejaculation after placement of an AMS 700 inflatable penile prosthesis improve over time?
What is the significance of an elevated DHEA‑sulfate level of 716 µg/dL and how should it be evaluated?
What are the renal‑failure‑adjusted chemical deep‑vein thrombosis prophylaxis doses for an adult on chronic hemodialysis with colon adenocarcinoma?
How should a widened QRS complex on an ECG be managed?
In a 12-year-old child with dry cough, expiratory wheezing, and nasal congestion but no prior history of asthma, what is the appropriate evaluation and management?
What chemical deep vein thrombosis prophylaxis regimen (drug, dose, timing, and duration) should be used after colon cancer resection in an adult patient with normal renal function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.